Search
CIGB-258 peptide
go.drugbank.com/drugs/DB15809ExperimentalAs of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens
Nalorphine
go.drugbank.com/drugs/DB11490ExperimentalVet approvedIt is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid dependence.
Idetrexed
go.drugbank.com/drugs/DB21469InvestigationalThe usage of the INN stem '-trexed' in the name indicates that Idetrexed is a antineoplastic; thymidilate synthetase inhibitor. … Idetrexed is under investigation in clinical trial NCT02360345 (Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly). Idetrexed has a monoisotopic molecular weight of 647.22 Da.
Eritoran
go.drugbank.com/drugs/DB04933InvestigationalEritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.
Bectumomab
go.drugbank.com/drugs/DB04962ExperimentalBectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it's used to treat non-Hodgkin's lymphoma. It has a radioisotope, technetium (99m TC) which it's added.
Anatibant
go.drugbank.com/drugs/DB05038ExperimentalAnatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).
EPC2407
go.drugbank.com/drugs/DB05189InvestigationalEPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. It is intended for the treatment of advanced cancer patients with solid tumors that...
Veltuzumab
go.drugbank.com/drugs/DB05656InvestigationalVeltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
IC41
go.drugbank.com/drugs/DB05776InvestigationalIC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C. The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell epitopes and the syn...